SpringerLink
Log in

Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The aim of this study is to investigate the role of FGF21 in obesity-related inflammation in livers of monosodium glutamate (MSG)-induced obesity rats. The MSG rats were injected with recombinant murine fibroblast growth factor 21(FGF21) or equal volumes of vehicle. Metabolic parameters including body weight, Lee’s index, food intake, visceral fat and liver weight, intraperitoneal glucose tolerance, glucose, and lipid levels were dynamically measured at specific time points. Liver function and routine blood test were also analyzed. Further, systemic inflammatory cytokines such as glucose transporter 1 (GLUT-1), leptin, TNF-α, and IL-6 mRNAs were determined by real-time PCR. FGF21 independently decreased body weight and whole-body fat mass without reducing food intake in the MSG rats. FGF21 reduced blood glucose level, Lee’s index, visceral fat, and liver weight, and improved glucose tolerance, lipid metabolic spectrum, and hepatic steatosis in the MSG-obesity rats. Liver function parameters including AST, ALT, ALP, TP, T.Bili, and D.Bili levels significantly reduced in the FGF21-treated obesity rats compared to the controls. Further, FGF21 ameliorated the total and differential white blood cell (WBC) count, serum C-reactive protein (CRP), IL-6, and TNF-α levels in adipose tissues of the obesity rats, suggesting inflammation amelioration in the in the obesity rats by FGF21. FGF21 improves multiple metabolic disorders and ameliorates obesity-related inflammation in the MSG-induced obesity rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. N. Itoh, D.M. Ornitz, Evolution of the Fgf and Fgfr gene families. Trends. Genet. 20, 563–569 (2004)

    Article  CAS  PubMed  Google Scholar 

  2. T. Nishimura, Y. Nakatake, M. Konishi, N. Itoh, Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492, 203–206 (2000)

    Article  CAS  PubMed  Google Scholar 

  3. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath et al., FGF-21 as a novel metabolic regulator. J Clin Invest. 115, 1627–1635 (2005)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits et al., FGF21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259 (2008)

    Article  PubMed  Google Scholar 

  5. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., FGF21 corrects obesity in mice. Endocrinology 149, 6018–6127 (2008)

    Article  CAS  PubMed  Google Scholar 

  6. A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno et al., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774–781 (2007)

    Article  CAS  PubMed  Google Scholar 

  7. A.H. Goris, K.R. Westerterp, Physical activity, fat intake and body fat. Physiol. Behav. 94, 164–168 (2008)

    Article  CAS  PubMed  Google Scholar 

  8. R.H. Unger, P.E. Scherer, Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol. Metab. 21, 345–352 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. M. Nagata, W. Suzuki, S. Iizuka, M. Tabuchi, H. Maruyama et al., Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp. Anim. 55, 109–115 (2006)

    Article  CAS  PubMed  Google Scholar 

  10. Y. Nakanishi, K. Tsuneyama, M. Fujimoto, T.L. Salunga, K. Nomoto, J.L. An et al., Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30, 42–50 (2008)

    Article  CAS  PubMed  Google Scholar 

  11. N. Aoi, M. Soma, T. Nakayama, D. Rahmutula, K. Kosuge, Y. Izumi et al., Variable number of tandem repeat of the 5’-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens. Res. 27, 711–716 (2004)

    Article  CAS  PubMed  Google Scholar 

  12. K. Kosuge, M. Soma, T. Nakayama, N. Aoi, M. Sato, A. Haketa et al., Human uncoupling protein 2 and 3 genes are associated with obesity in Japanese. Endocrine 34, 87–95 (2008)

    Article  CAS  PubMed  Google Scholar 

  13. K. Strohacker, B.K. McFarlin, Influence of obesity, physical inactivity, and weight cycling on chronic inflammation. Front Biosci (Elite Ed). 2, 98–104 (2010)

    Article  CAS  PubMed  Google Scholar 

  14. I. Majumdar, L.D. Mastrandrea, Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 41, 442–449 (2012)

    Article  CAS  PubMed  Google Scholar 

  15. P. Marzullo, A. Minocci, P. Giarda, C. Marconi, A. Tagliaferri, G.E. Walker, M. Scacchi, G. Aimaretti, A. Liuzzi, Lymphocytes and immunoglobulin patterns across the threshold of severe obesity. Endocrine 45, 392–400 (2014)

    Article  CAS  PubMed  Google Scholar 

  16. M. Rondanelli, A. Opizzi, S. Perna, M. Faliva, S.B. Solerte, M. Fioravanti, C. Klersy, E. Cava, M. Paolini, L. Scavone, P. Ceccarelli, E. Castellaneta, C. Savina, L.M. Donini, Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months’ consumption of a combination of bioactive food ingredients in overweight subjects. Endocrine 44, 391–401 (2013)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, V. Parameswara et al., Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415–425 (2007)

    Article  CAS  PubMed  Google Scholar 

  18. A. Kharitonenkov, A.B. Shanafelt, Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs. 22, 37–44 (2008)

    Article  CAS  PubMed  Google Scholar 

  19. T. Nakagawa, K. Ukai, T. Ohyama, Y. Gomita, H. Okamura, Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp. Anim. 49, 239–249 (2000)

    Article  CAS  PubMed  Google Scholar 

  20. M. Nagata, W. Suzuki, S. Iizuka, M. Tabuchi, H. Maruyama, S. Takeda et al., Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp. Anim. 55, 109–115 (2006)

    Article  CAS  PubMed  Google Scholar 

  21. S.M. Kang, J.W. Yoon, H.Y. Ahn, S.Y. Kim, K.H. Lee, H. Shin et al., Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS ONE 6, e27694 (2011)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. J. Liu, F. Zhang, C. Li, M. Lin, M.R. Briggs, Synergistic activation of human LDL receptor expression by SCAP ligand and cytokine oncostatin M. Arterioscler. Thromb. Vasc. Biol. 23, 90–96 (2003)

    Article  PubMed  Google Scholar 

  23. S.M. Grundy, Statin trials and goals of cholesterol-lowering therapy. Circulation 97, 1436–1439 (1998)

    Article  CAS  PubMed  Google Scholar 

  24. E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, A.B. Shanafelt et al., Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084–4093 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. F.M. Fisher, P.C. Chui, P.J. Antonellis, H.A. Bina, A. Kharitonenkov, J.S. Flier et al., Obesity is an FGF21 resistant state. Diabetes 59, 2781–2789 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. T. Lundåsen, M.C. Hunt, L.M. Nilsson, S. Sanyal, B. Angelin, S.E. Alexson et al., PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 360, 437–440 (2007)

    Article  PubMed  Google Scholar 

  27. Y.L. Zhang, A. Hernandez-Ono, P. Siri, S. Weisberg, D. Conlon, M.J. Graham et al., Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J. Biol. Chem. 281, 37603–37615 (2006)

    Article  CAS  PubMed  Google Scholar 

  28. J.S. Moyers, T.L. Shiyanova, F. Mehrbod, J.D. Dunbar, T.W. Noblitt, K.A. Otto et al., Molecular determinants of FGF-21 activity - synergy and cross-talk with PPARγ signaling. J. Cell. Physiol. 210, 1–6 (2007)

    Article  CAS  PubMed  Google Scholar 

  29. H. Wang, L. Qiang, S.R. Farmer, Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28, 188–200 (2008)

    Article  PubMed Central  PubMed  Google Scholar 

  30. Z. Wang, T. Nakayama, Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010, 535918 (2010)

    Article  PubMed Central  PubMed  Google Scholar 

  31. Tamer Coskn, Holly au Bina, Michael a Schneider, James D Dunbar, Charlie C Hu, Yanyun Chen, David E Moller, and Alexei Kharitonenkov. “Fibroblast Growth Factor 21 Corrects Obesity in Mice”. Endocrinology 149, 6018–6027 (2008)

    Article  Google Scholar 

  32. M.J. Potthoff, T. Inagaki, S. Satapati, X. Ding, T. He, R. Goetz et al., FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 106, 10853–10858 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Nos.81172741 and 30972537).

Conflict of interest

The authors declare that there is no conflict of interest in this study.

Author information

Authors and Affiliations

  1. College of Life Science, Northeast Agricultural University, 59 Mucai Street, **angfang District, Harbin, 150030, China

    Wen-Fei Wang, Si-Ming Li, Gui-** Ren, Yin-Hang Yu, Wen-Juan Xu & De-Shan Li

  2. Harbin University of Commerce, Harbin, 150028, China

    Si-Ming Li, Wei Zheng & Yu-Jia Lu

  3. College of Life Sciences, University of Chinese Academy of Sciences, Bei**g, 100049, China

    Tian-He Li

  4. Department of Endocrinology, The First Affiliated Hospital, Harbin Medical University, 31 Xuefu Road, Nangang District, Harbin, 150010, China

    Li-Hong Zhou

  5. Department of Biostatistics, School of Public Health, Harbin Medical University, 194 Xuefu Road, Nangang District, Harbin, 150010, China

    Yan Liu

Authors
  1. Wen-Fei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Si-Ming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gui-** Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Jia Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yin-Hang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-Juan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tian-He Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Li-Hong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. De-Shan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Li-Hong Zhou, Yan Liu or De-Shan Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, WF., Li, SM., Ren, GP. et al. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine 49, 119–129 (2015). https://doi.org/10.1007/s12020-014-0433-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0433-5

Keywords

Search

Navigation